Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis

<p><b>Objective</b></p> We assessed and compared immunologic differences and associations with clinical response to guselkumab, a fully human interleukin (IL)–23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) who were biologic-naive or had inadequ...

Celý popis

Podrobná bibliografie
Hlavní autoři:	Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A
Médium:	Journal article
Jazyk:	English
Vydáno:	Wiley 2024

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis Autor Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A

Vydáno 2024

Journal article

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis

Podobné jednotky